glp-1 receptor agonists and cancer risk in adults with obesity a major new JAMA Oncology study, researchers examined health records from 86,632 obesity, comparing those who used (like semaglutide or tirzepatide) to matched non-users. The findings GLP-1 Receptor Agonists and Cancer

The synovium can change early in OA, even before cartilage breaks down

Exenatide extended-release (ER) , taken weekly: FDA-approved under the brand name Bydureon to treat type 2 diabetes

(54) found that administering GIPR antagonist to healthy humans reduced postprandial insulin secretion and increased glucose excursions more than administering GLP-1R antagonist (GLP-1RA), indicating that endogenous GIP may play a more significant role in stimulating insulin secretion and reducing postprandial plasma glucose excursions compared to endogenous GLP-1

The ITE distributions are shown in eResults 3 in Supplement 1

PEX-168 is a new agent of long-acting GLP-1R agonist, which is molecularly modified from EX via amino acid modification and PEGylation (119), the first GLP-1R agonist modified by PEG to achieve long-term pharmacological action (120, 121)

95% CI 0.79 0.99